Review Article
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
Lisa Barbarotta, RN, MSN, AOCNS®, APRN-BC1, and Kristen Hurley, RN, MSN, CNP2
1Hematology-Oncology Service, Smilow Cancer Hospital, Yale New Haven, Connecticut; 2Avera Medical Group, Hematology and Bone Marrow Transplantation, Sioux Falls, South Dakota
Authors’ disclosures of potential conflicts of interest are found at the end of this article.
Lisa Barbarotta, RN, MSN, AOCNS®, APRN-BC, Hematology-Oncology
Service, Smilow Cancer Hospital at Yale New Haven, 20 York Street, New Haven, CT 06510.
E-mail: lisa.barbarotta@ynhh.org
J Adv Pract Oncol 2015;6:22–36 |
DOI: 10.6004/jadpro.2015.6.1.3 |
© 2015 Harborside Press®
ABSTRACT
Peripheral T-cell lymphomas (PTCLs) are a rare, heterogeneous group of T-cell– or natural killer cell–derived non-Hodgkin lymphomas. The majority of patients with PTCL experience an aggressive disease course and poor overall survival. Historically, PTCL has been treated with chemotherapy regimens used to treat B-cell lymphomas; however, a lack of durable responses to frontline therapies and few effective options for salvage treatment have led to the development of newer therapies. Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone deacetylase (HDAC) inhibitor that has demonstrated durable clinical responses in patients with relapsed/refractory PTCL, leading to its approval by the US Food and Drug Administration in 2011 for the treatment of PTCL in patients who have received at least one prior therapy. Here, the authors provide an overview of PTCL, review the role of HDAC inhibitors as anticancer agents, discuss romidepsin use in PTCL, and highlight considerations for advanced practitioners (including the management of side effects).
For access to the full length article, please
sign in.
